Navigation Links
Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Date:10/25/2007

er the process for manufacturing HIF-1a from Genzyme to Sunway, the extent to which HIF-1a is ultimately demonstrated to be safe and effective, Sunway's ability to manufacture sufficient product supply and to distribute the product in a timely and effective manner to support the necessary clinical trials and commercialization, the ability to obtain marketing approval within the territory, the size of the market in the territory for the therapy, actions by governmental authorities related to HIF-1a, and the other risks and uncertainties described in reports filed by Genzyme with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, including without limitation the information under the heading "Risk Factors" in the Management's Discussion and Analysis of Financial Condition and Results of Operations section of the Genzyme Quarterly Report on Form 10-Q for the quarter ending June 30, 2007. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of the date of this press release, and Genzyme undertakes no obligation to update or revise the statements.

Genzyme(R) is a registered trademark of Genzyme Corporation. All rights reserved.

Genzyme's press releases and other company information are available at http://www.genzyme.com and by calling Genzyme's investor information line at 1-800- 905-4369 within the United States or 1-678-999-4572 outside the United States.

Media Contact: Investor Contact:

Bo Piela Patrick Flanigan

617-768-6579 617-768-6563


'/>"/>
SOURCE Genzyme Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cytochroma settles lawsuit with Genzyme
2. Genzyme sues former Bone Care employees
3. Genzyme acquistion of Bone Care approved, significant impact forecast
4. GE, St. Jude to collaborate on visualization technology
5. GE Healthcare, MobileAccess to collaborate on hospital wireless
6. GE Healthcare, Harvard medical school to collaborate on nervous system research
7. Madison, Milwaukee med schools to collaborate on tech transfer
8. EraGen collaborates with Emory University on HIV detection system
9. The Genesis of Gendicine: The Story Behind the First Gene Therapy
10. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
11. TomoTherapy opens technical training center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... Noblis, Inc., ... announced in a paper published this week in the scientific journal Viruses ( ... diagnostic techniques currently used to detect the Ebola virus. Noblis worked with the ...
(Date:6/30/2015)... ... , ... Matrix Marketing Group, LLC , a leading provider of performance-based ... up its account management department as vice president of client services. Amanda Gregory ... management and delivery expertise to the growing Matrix Marketing Group team in Denver, Colorado. ...
(Date:6/30/2015)... -- Custom Computer Specialists, Inc. ("Custom"), a leading healthcare IT ... of the Primary Care Development Corporation,s ("PCDC") Corporate Circle. ... support of PCDC,s mission to expand access to primary ... in 1993, PCDC has been a key force of ... over 100 completed primary care projects, valued at over ...
(Date:6/30/2015)... , June 30, 2015  The Dr. Samadi Prostate ... is now offering a full suite of new genetic testing ... a biopsy, for diagnosing prostate cancer. ... of genetic tests for assessing the risk and optimizing the ... "We,re very excited to now offer these revolutionary genetic ...
Breaking Biology Technology:Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 2Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 3Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 4Matrix Marketing Group Expands Client Services Team 2Custom Computer Specialists Announces Sponsorship Of The Primary Care Development Corporation's Corporate Circle 2New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 2New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 3New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 4New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 5
... ... CUNY Nobel Science Challenge. , ... New York, NY (Vocus) March 12, 2010 -- Borough of Manhattan Community College (BMCC) ... 2009 CUNY Nobel Science Challenge—as well as $5,000 as an overall Grand Prizewinner., , , ...
... Food and Drug Administration (FDA) has approved a five-day dosing regimen for Dacogen® (decitabine) for Injection to treat patients with myelodysplastic syndromes (MDS), a group of ... ... , ... ...
... ... , ... ... EDMONTON , March 11 /PRNewswire/ - Today at ACAMP,s ...
Cached Biology Technology:BMCC Student—the Only Community College Winner—Lands Grand Prize in Nobel Science Challenge 2FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 2FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 3FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 4FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 5FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 6FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 7FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 8Alberta companies delivering new products to the Conventional Energy marketplace 2Alberta companies delivering new products to the Conventional Energy marketplace 3
(Date:6/25/2015)...  Imagine a tool specifically designed to help you ... That,s exactly what USANA,s True Health Assessment ... health program provides a personalized approached to measuring your ... lifestyle and nutrition. At the Canadian ... USANA,s THA was honored with the Industry Innovation Award. ...
(Date:6/24/2015)... -- The biologics safety testing market is growing at ... include growth of the pharmaceutical and biological industries and ... years, the number of drug approvals in North American ... approved 225 drug applications and Health Canada approved 99. ... accounted for 3,822 of the pharmaceutical and 1,998 ...
(Date:6/24/2015)... , June 24, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced that Sharp has selected ... secure authentication for its latest flagship smartphone device, ... than 200 million shipments of its fingerprint ID ... Synaptics, strength, scalability and leadership in the biometrics ...
Breaking Biology News(10 mins):@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2
... causing urinary tract infections (UTIs), the second-most-common infection in ... with current antibiotics, according to new research from Extending ... Disease Dynamics, Economics & Policy. ETC released the ... to track changes in antibiotic drug use and resistance. ...
... Nov. 13, 2012 Millions of laboratory tests and ... processes. Quantum Materials Corporation has now developed tetrapod ... gain knowledge of how body systems function and chronic ... health and longevity. Conventionally, fluorescent tags or ...
... $15,000 in a national competition for adapting a traditional ... villagers can use to make paper for their children,s ... of a machine to convert farm waste to paper, ... Houston during a ceremony honoring top submissions in the ...
Cached Biology News:Second most common infection in the US proving harder to treat with current antibiotics 2Second most common infection in the US proving harder to treat with current antibiotics 3Second most common infection in the US proving harder to treat with current antibiotics 4High Brightness Tetrapod Quantum Dots Developed 2High Brightness Tetrapod Quantum Dots Developed 3Plan to turn farm waste into paper earns students $15,000 2
... smallest electronic pressure controller available measuring 26 ... this unit specifically for the analytical instrumentation ... carrier gas flow control, microfluidic flow control, ... focusing, the OEM-EPC offers external pressure sensor ...
... Flow) offers the same benefits as the VSO ... control is critical or flow is required below ... flow of gas in proportion to the input ... pulse width modulation; closed loop feedback delivers optimal ...
...
... Serum is obtained from non-demolished ... healthy, fasted donors. The donors ... way and are maintained on ... Total Protein Concentration : 85 ...
Biology Products: